Your browser doesn't support javascript.
loading
p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
Giorgi Rossi, Paolo; Carozzi, Francesca; Ronco, Guglielmo; Allia, Elena; Bisanzi, Simonetta; Gillio-Tos, Anna; De Marco, Laura; Rizzolo, Raffaella; Gustinucci, Daniela; Del Mistro, Annarosa; Frayle, Helena; Confortini, Massimo; Iossa, Anna; Cesarini, Elena; Bulletti, Simonetta; Passamonti, Basilio; Gori, Silvia; Toniolo, Laura; Barca, Alessandra; Bonvicini, Laura; Mancuso, Pamela; Venturelli, Francesco; Benevolo, Maria.
Affiliation
  • Giorgi Rossi P; Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Carozzi F; ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Florence, Italy.
  • Ronco G; International Agency for Research on Cancer, Lyon, France.
  • Allia E; Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Turin, Italy.
  • Bisanzi S; Center for Cervical Cancer Screening, City of Health and Science Hospital, Turin, Italy.
  • Gillio-Tos A; ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Florence, Italy.
  • De Marco L; Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Turin, Italy.
  • Rizzolo R; Center for Cervical Cancer Screening, City of Health and Science Hospital, Turin, Italy.
  • Gustinucci D; Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Turin, Italy.
  • Del Mistro A; Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Turin, Italy.
  • Frayle H; Laboratorio Unico di Screening, Unità Sanitaria Locale Umbria1, Perugia, Italy.
  • Confortini M; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
  • Iossa A; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
  • Cesarini E; ISPRO Oncological Network, Prevention and Research Institute, Regional Laboratory of Cancer Prevention Unit, Florence, Italy.
  • Bulletti S; ISPRO Oncological Network, Prevention and Research Institute, Screening Unit, Florence, Italy.
  • Passamonti B; Laboratorio Unico di Screening, Unità Sanitaria Locale Umbria1, Perugia, Italy.
  • Gori S; Laboratorio Unico di Screening, Unità Sanitaria Locale Umbria1, Perugia, Italy.
  • Toniolo L; Laboratorio Unico di Screening, Unità Sanitaria Locale Umbria1, Perugia, Italy.
  • Barca A; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
  • Bonvicini L; Assessorato alla Salute, Regione Lazio, Rome, Italy.
  • Mancuso P; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Venturelli F; Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Benevolo M; Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
J Natl Cancer Inst ; 113(3): 292-300, 2021 03 01.
Article in En | MEDLINE | ID: mdl-32745170
ABSTRACT

BACKGROUND:

The study presents cross-sectional accuracy of E6 and E7 (E6/E7) mRNA detection and p16/ki67 dual staining, alone or in combination with cytology and human papillomavirus (HPV)16/18 genotyping, as a triage test in HPV DNA-positive women and their impact on cervical intraepithelial neoplasia (CIN2+) overdiagnosis.

METHODS:

Women aged 25-64 years were recruited. HPV DNA-positive women were triaged with cytology and tested for E6/E7 mRNA and p16/ki67. Cytology positive women were referred to colposcopy, and negatives were randomly assigned to immediate colposcopy or to 1-year HPV retesting. Lesions found within 24 months since recruitment were included. All P values were 2-sided.

RESULTS:

40 509 women were recruited, and 3147 (7.8%) tested HPV DNA positive; 174 CIN2+ were found sensitivity was 61.0% (95% confidence interval [CI] = 53.6 to 68.0), 94.4% (95% CI = 89.1 to 97.3), and 75.2% (95% CI = 68.1 to 81.6) for cytology, E6/E7 mRNA, and p16/ki67, respectively. Immediate referral was 25.6%, 66.8%, and 28.3%, respectively. Overall referral was 65.3%, 78.3%, and 63.3%, respectively. Cytology or p16/ki67, when combined with HPV16/18 typing, reached higher sensitivity with a small impact on referral. Among the 2306 HPV DNA-positive and cytology-negative women, relative CIN2+ detection in those randomly assigned at 1-year retesting vs immediate colposcopy suggests a -28% CIN2+ regression (95% CI = -57% to +20%); regression was higher in E6/E7 mRNA-negatives (Pinteraction = .29). HPV clearance at 1 year in E6/E7 mRNA and in p16/ki67 negative women was about 2 times higher than in positive women (Pinteraction < .001 for both).

CONCLUSIONS:

p16/ki67 showed good performance as a triage test. E6/E7 mRNA showed the highest sensitivity, at the price of too high a positivity rate to be efficient for triage. However, when negative, it showed a good prognostic value for clearance and CIN2+ regression.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Uterine Cervical Dysplasia / Uterine Cervical Neoplasms / Oncogene Proteins, Viral / Ki-67 Antigen / Cyclin-Dependent Kinase Inhibitor p16 / Papillomavirus Infections Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: J Natl Cancer Inst Year: 2021 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA, Messenger / Uterine Cervical Dysplasia / Uterine Cervical Neoplasms / Oncogene Proteins, Viral / Ki-67 Antigen / Cyclin-Dependent Kinase Inhibitor p16 / Papillomavirus Infections Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: J Natl Cancer Inst Year: 2021 Document type: Article Affiliation country: Italy